MEDICINE DETAILS
Adzynma
Active ingredient: Adamts13
Adzynma is recorded in this directory with the active ingredient Adamts13. This page brings together catalogue strength, dosage-form and pack records so they can be checked against a prescription.
NEXT STEP
Choose the strength and pack
✓ If you are unsure, choose “I do not know”.
These options are not medical advice, a dosing recommendation, stock confirmation or a sale offer.
ABOUT THIS MEDICINE
What is Adzynma used for?
Adzynma (ADAMTS13, recombinant-krhn) is a lab-made version of the human enzyme ADAMTS13. It is indicated for the treatment of adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP). Adzynma (ADAMTS13, recombinant-krhn) can be used as prophylactic or on-demand therapy.
Adzynma (ADAMTS13, recombinant-krhn) is administered as an intravenous injection. It is available as a lyophilized powder for reconstitution, in single-dose vials containing 500 or 1500 international units.
This information is general and is not medical advice. Talk to your doctor or pharmacist about any treatment decision.
RECORDED PRODUCT PROFILE
Adzynma identity, dosage form and pack information.
The details below are assembled from current catalogue records. They must still be checked against the prescription, medicine box and an official regulatory record.
Recorded strength and pack options
Each row is shown only to help identify the product; it is not stock confirmation or a sale offer.
-
500 IU · 1 powder and solvent set Catalogue organisation: TAKEDA GmbH
-
1500 IU · 1 powder and solvent set Catalogue organisation: TAKEDA GmbH
OFFICIAL SOURCES
Check the Adzynma record at an official source.
Search for “Adzynma” or “Adamts13”. Finding a product in one source does not by itself confirm stock, authorisation in a particular country or suitability for a patient.
OFFICIAL EXTERNAL SOURCE
European Medicines Agency (EMA)
Search medicines evaluated by EMA by brand name or active substance. EMA also links to national registers for nationally authorised products.
↗ OFFICIAL EXTERNAL SOURCE Drugs@FDASearch FDA-approved human drug records by brand name or active ingredient, including current labelling where available.
↗SERVICE BOUNDARY
Information checking and independent enquiry support for Adzynma.
OrphanDrug helps organise the product identity and recorded strength and pack details for an enquiry. It does not sell, take payment for, prescribe, import, dispense or deliver medicines.
Clinical decision: Only a qualified healthcare professional who has assessed the patient can decide whether a product, form or dose is appropriate.
CLEAR ANSWERS
Frequently asked questions about Adzynma
01What is Adzynma?＋
This directory record associates the brand name Adzynma with the active ingredient Adamts13. The brand and ingredient are shown for product identification only, not as treatment or dosing advice.
02Which Adzynma strengths and packs are recorded?＋
The catalogue currently shows: 500 IU · 1 powder and solvent set; 1500 IU · 1 powder and solvent set. Check the complete strength, dosage form and pack description against the prescription and medicine box.
03Who manufactures Adzynma?＋
Catalogue records currently name: TAKEDA GmbH. This field may identify a manufacturer, marketing-authorisation holder, marketing company or supplier; confirm the exact role on the pack leaflet and official regulatory record.
04Do the listed options confirm stock or access?＋
No. A catalogue record does not confirm current stock, authorisation in a particular country, clinical suitability, import permission or access.
05What affects a possible estimated medicine cost for Adzynma?＋
A possible cost depends on the exact strength, dosage form, pack, quantity, destination and regulatory jurisdiction. Any amount provided after an enquiry is an indicative medicine-cost estimate only, not a selling price for Adzynma, payment request, stock guarantee or binding offer.
06Can I buy Adzynma from this website?＋
No. This website does not sell, take payment for, prescribe, import, dispense or deliver medicines. The form creates an independent consultancy enquiry only.